

PACIFIC DIAGNOSTIC LABORATORIES  
 SBCH<sup>8</sup> only  
 Antimicrobial Susceptibility Profile January thru December 2010  
 Percent Susceptible<sup>1</sup>

ORGANISM <sup>1</sup>	AVG. SAMPLE SIZE	AMPICILLIN	AMP / SUL	NAFCIL/OXACIL	PIP / TAZO	TETRACYCLINE	CEFAZOLIN	TIGECYCLINE	CEFOTETAN	CEFTAZIDIME	CEFTRIAXONE	CIPROFLOXACIN	LEVOFLOXACIN	GENTAMICIN	IMPENEM	ERTAPENEM	TRIMET/SULFA	NITROFURAN (3)	CLINDAMYCIN	ERYTHROMYCIN	VANCOMYCIN	LINEZOLID	RIFAMPIN (4)
<i>Escherichia coli</i> (9)	1334	52	67		93		90	100	97	95	95	80	81	89	100	100	72	95					
<i>Escherichia coli</i> , urines only (9)	1026	53	68		95		91		97	96	96	80	81	88	100	100	74	94					
<i>Klebsiella</i> species (9)	306	0	85		96		92	95	98	97	97	98	98	99	100	100	93	24					
<i>Pseudomonas aeruginosa</i>	312				87		0		0	84		76		87	80								
<i>Enterobacter</i> species	174	0	16		72		0	91	11	73	75	96	96	99	98	96	95	20					
<i>Proteus mirabilis</i>	121	81	88		97		89	68	95	93	93	87	89	93	99	100	83	0					
<i>Serratia marcesans</i>	44	43	43		98		0	93	95	91	95	84	83	100	98	98	100	0					
<i>Hemophilus influenza</i>	95	90																					
<i>S. maltophilia</i>	43									29			88				100						
<b>Staphylococcus aureus (overall)</b>	<b>712</b>		<b>(2)</b>	<b>56</b>		<b>92</b>	<b>(2)</b>						<b>52<sup>7</sup></b>	<b>99</b>			<b>98</b>	<b>98</b>	<b>76</b>	<b>41</b>	<b>100</b>	<b>100</b>	<b>99</b>
<i>Staphylococcus aureus</i> (MSSA)	722			100		93							81 <sup>7</sup>	100			98	97	84	65	100	100	100
<i>Staphylococcus aureus</i> (MRSA)	568			0		91	0						14 <sup>7</sup>	99			97	99	64	10	100	100	99
<b>Enterococcus (overall)</b>	<b>432</b>	<b>78</b>																			<b>86</b>	<b>81</b>	
<i>Enterococcus</i> species	310	92																			100	81	
<i>Enterococcus faecium</i>	68	9																			13	86	
<i>Enterococcus faecalis</i>	54	84																			100	76	
<i>Enterococcus</i> species, urines only	226	92											70 <sup>6</sup>					95			100	81	
Coagulase negative Staph.	167	(2)	(2)	36		83	(2)						54 <sup>7</sup>				68	99	64	38	100	100	96
<i>Streptococcus pneumoniae</i>	48																				67		
<i>Streptococcus pneumoniae</i> (5)	20									94		96					40				100		

**Footnotes:**

1. Profiles include data from disk diffusion, automated testing and gradient diffusion MIC. Intermediate results have been interpreted as resistant for this tabulation. All isolates were not tested against each antibiotic in the profile.
2. Refer to oxacillin results. Oxacillin resistant strains may not respond to beta lactam antibiotics such as penicillins, cephalosporins and imipenem.
3. Data apply only to organisms isolated from urinary tract.
4. Rifampin should not be used as a sole agent for antimicrobial therapy.
5. *S. pneumoniae* isolates that were either penicillin resistant or from sterile sites. (Overall 65% susceptible to Pen.)
6. Fluoroquinolones are generally not an appropriate therapy against enterococcus infections from sites other than urine.
7. *Staphylococcus* isolates may become resistant to fluoroquinolones within 3-4 days after initiation of therapy. (NCCLS M100-S14,2004)
8. 2010 Antibiogram Statistics was compiled from isolates from SBCH patient locations only.
9. ESBL rate for *E. coli* and *Klebsiella* combined for 2010 is approximately 2%.

**PACIFIC DIAGNOSTIC LABORATORIES  
SANTA BARBARA, CA**

**ANTIBIOTIC SUSCEPTIBILITY PROFILES  
2010  
SBCH location only**

**DEPARTMENTS OF MICROBIOLOGY**

**MANAGER:  
Marian Jean, CLS(ASCP)  
805-879-8185  
Email (mjean@sbch.org)**